Cancer remains one of the biggest health challenges facing our society. Despite remarkable advances in medicine, many cancers are still difficult to treat, particularly aggressive tumours that stop responding to therapy. These cancers can learn how to fight back against current standard-of-care treatment options, spread to other parts of the body, and return after periods of remission, leaving patients with limited options.
Dr. Debottam Sinha’s research focuses on understanding how cancer cells survive and adapt under pressure from treatments and the body’s immune system. He investigates the biological processes that enable cancer cells to evade destruction and continue growing despite therapies designed to eliminate them.
By uncovering these hidden defence mechanisms, Dr. Sinha aims to identify new vulnerabilities that can be targeted with more effective treatments. His work seeks to improve outcomes for patients with hard-to-treat cancers and support the development of more personalised approaches to cancer care.
Dr. Debottam Sinha is uncovering how cancers adapt, survive, and evade both treatment and the body’s immune system. His research has revealed important molecular pathways that drive drug resistance, providing new opportunities to target cancers that currently have limited treatment options.
Using cutting-edge multiomics technology, Dr. Sinha examines the activity of thousands of genes, proteins, and metabolites within cancer cells to build a comprehensive picture of how tumors evolve in response to therapy. By integrating these powerful approaches, he can identify the biological vulnerabilities that cancers rely on for survival.
To translate these discoveries into new treatments, Dr. Sinha is developing advanced laboratory models that closely mimic human cancer. Combining cancer biology, immunology, and state-of-the-art imaging technologies, his team is testing innovative therapeutic strategies and identifying the most promising combinations for future clinical development.
Ultimately, his research aims to accelerate the development of personalized cancer treatments that are more effective, more durable, and better able to improve outcomes for patients with hard-to-treat cancers.